LLY
股票Eli Lilly and Co
- 总部
- US
- 行业
- 制药
- 发行时间
- 1985-01-13
- 流通股
- 942M
区间表现
1 小时前关键指标
1 小时前- 市值
- $1.02T
- 企业价值
- $1.05T
- 市盈率 (TTM)
- 40.16
- 预期市盈率
- 27.51
- 市盈率 (年)
- 49.19
- PEG
- 1.37
- 市净率
- 38.29
- 市销率 (TTM)
- 14.05
- 市销率 (年)
- 15.58
- EV / EBITDA
- 31.38×
- EV / 营收
- 14.58×
- 每股收益 (TTM)
- $28.15
- 每股收益 (年)
- $22.95
- 基本每股收益 (TTM)
- $28.15
- 每股净资产
- $28.09
- 毛利率
- 82.83%
- 营业利润率
- 43.63%
- 净利率
- 34.99%
- 净资产收益率 (ROE)
- 101.31%
- 总资产收益率 (ROA)
- 22.73%
- 投资回报率 (ROI)
- 37.71%
- 每股 EBITDA
- $37.37
- 每股营收 (TTM)
- $80.64
- 营收增长 (TTM YoY)
- +47.44%
- 营收增长 (季 YoY)
- +55.55%
- EPS 增长 (TTM YoY)
- +128.83%
- 股息率 (预期)
- 0.64%
- 股息率 (TTM)
- 0.55%
- 每股股息 (TTM)
- $5.91
- 派息率
- 22.10%
- 流动比率
- 1.58
- 速动比率
- 0.78
- 负债权益比
- 1.60
- 长期负债权益比
- 1.54
- Beta
- 0.52
- 波动率 (3M)
- 37.57%
分析师评级
1 小时前财报
1 小时前相关新闻
1 小时前- Yahoo·1 天前companyHanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)
Hanmi Pharm. Co., Ltd. ("Hanmi") today announced that they have entered into a license agreement for the development, manufacturing and commercialization of Hanmi's biologic drug candidate sonefpeglutide (LAPSGLP-2 analog) with Eli Lilly and Company ("Lilly").
- Yahoo·2 天前companyCould GLP-1 drugs become oncology’s next big opportunity?
Investing.com -- GLP-1 weight-loss and diabetes drugs may have a future role in cancer prevention and treatment, according to new research highlighted by Citi ahead of the 2026 American Society of Clinical Oncology (ASCO) meeting, adding another potential growth avenue to an already booming drug class.
- Yahoo·2 天前companyEli Lilly sends strong message on vaccine strategy
Shingles is no minor inconvenience. Ask anyone who has had it and they will tell you the burning, nerve-rattling pain can last for days. But what if surviving shingles was only half the battle? New research suggests the virus behind it could raise your risk of stroke and dementia years after the ...
- Yahoo·2 天前companyLilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo in patients with early-stage (IB-IIIA) rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in investigator-assessed event-free survival (EFS) with selpercatinib reducing the r
- Yahoo·3 天前companyEli Lilly and Company (LLY): A Long Term Stock to Buy
Eli Lilly and Company (NYSE:LLY) is one of the top long-term stocks to buy. On May 25, Eli Lilly and Company (NYSE:LLY) delivered positive Phase 1b Heart-2 study results for VERVE-102, an investigational base-editing therapy designed to deactivate the PCSK9 gene in the liver. The trial results show that VERVE-102 successfully reduced PCSK9 by up […]
- Yahoo·3 天前companyLilly's New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Here's What It Means for Investors
Eli Lilly is working on a new GLP-1 drug, and early results suggest it could be a big winner.
- Yahoo·3 天前companyCVS Decision Tests Novo Nordisk Wegovy Edge And Valuation Story
CVS Caremark has granted preferred formulary status to both Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo. This decision reverses Wegovy's prior commercial advantage within CVS Caremark's GLP-1 obesity drug coverage. The change affects access and competitive positioning for GLP-1 obesity therapies in CVS Caremark's network. Novo Nordisk, listed as CPSE:NOVO B, is a key player in GLP-1 based therapies, with Wegovy at the center of its obesity drug portfolio. CVS Caremark's move...
- Yahoo·3 天前companyStock Split Watch: Is Eli Lilly Next?
Lilly has split its stock in the past.
